The Efficacy of Individualized PEG-IFNalpha-2a Therapy in Patients with Chronic Hepatitis B and the Association between Efficacy and Hepatic Histology

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCC-12002196

Enrollment

Unknown

Registered

2012-05-24

Start date

2005-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

one:prolonged treatment group received 72 weeks of treatment

two:combination with entecavir

three:combination with adefovir dipivoxil

four:combination with adefovir dipivoxil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were: HBV DNA >=104 copies/mL (or HBV DNA >=300 copies/mL for patients with hepatitis B cirrhosis); alanine aminotransferase (ALT) >=upper limit of normal (ULN) and =4 or >=G2 inflammation and necrosis on the liver biopsy.

Exclusion criteria

Exclusion criteria: The exclusion criteria were: pregnancy or lactation; decompensated cirrhosis; history of psychiatric disorders, epilepsy, malignancies, or symptomatic heart diseases; history of drug or alcohol abuse; and co-infection with HCV, HDV, and HIV.

Design outcomes

Primary

Measure	Time frame
HBV DNA;quantitative HBsAg;	—

Secondary

Measure	Time frame
liver function;serum HBV biomarkers;Knodell HAI;	—

Countries

China

Contacts

Public ContactWang Jiangbin

zrlwangjb@medmail.com.cn+86 0431 84995303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 9, 2026